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New sensitive genotyping technologies can detect low level
drug resistant variants that are often missed by standard
methods. New technologies have the potential to help the
field investigate important viral population characteristics
which may impact antiretroviral treatment responses. Spe-
cific viral factors such as the number of viral variants with
drug resistance mutations in the circulating quasispecies
(resistance mutational load), genetic linkage (mutations
within the same viral genome), and specific mutation pat-
terns may all impact treatment response. The detection
level for particular resistance mutations and the relative
mutational loads required to predict virologic failure for
different regimens requires better definition. The ability to
identify mutation linkage may improve the prediction of
virologic failure. It should be emphasized that not all low
level resistant variants lead to virologic failure as other
active agents in a regimen (with different genetic barriers)
may suppress the resistant variant. New sensitive genotyp-
ing methods have limitations due to both the inability to
extract a fully representative sample of all viral variants
present in blood and by the intrinsic error rates of the
enzymatic and detection processes employed. These lim-
itations can lead to discordant results between different
sensitive technologies. The impact of low level resistant
variants on treatment response is likely a multifactorial
process with mutation load, linkage, and the genetic bar-
rier of the regimen all contributing. The development of
new genotypic resistance technology will allow the field to
examine how these factors interact and impact therapy.
This paper will describe some of the new sensitive tech-
nologies to detect genotypic drug resistance and the
important questions that need to be addressed to help
improve their clinical utility.
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